



XINTELA SIGNS MEMORANDUM OF UNDERSTANDING WITH CO.DON

Lund, Sweden, 22nd of May 2017 – Xintela AB (publ) announces today that the company has signed a non-binding Memorandum of Understanding with the leading European cell therapy company, CO.DON. The parties intend to collaborate on the development of Xintela's quality markers for CO.DON's next cell-based product and for the co-development of Xintela's stem cell product for the treatment of osteoarthritis.

The Memorandum of Understanding follows from the positive results of the validation of Xintela's quality assurance assay, XACT™, which was carried out together with CO.DON. It means the two companies will now take the next step towards a deeper, product development-focused collaboration.

"Last year we completed a very successful collaboration with CO.DON to validate Xintela's markers for quality assurance of CO.DON's cartilage cells. CO.DON is one of the leading regenerative medicine companies in Europe and we look forward to reaching definitive agreements to start developing these new business opportunities", says Xintela's CEO Evy Lundgren-Åkerlund.

About CO.DON

CO.DON AG develops, produces and markets in Germany autologous cell therapies for the minimally invasive repair of cartilage damage in joints following traumatic or degenerative defects. CO.DON condrosphere® is a cell therapy product that uses only the patient's own cartilage cells ("autologous chondrocytes"). CO.DON condrosphere® has been approved by the German federal agency PEI in accordance with Section 4b of the German Pharmaceuticals Act (AMG) and is currently undergoing Phase II and III clinical trials to obtain European marketing authorisation. CO.DON condrosphere® has been used for more than 10 years in over 150 clinics to treat more than 11,000 patients. In Germany the statutory health insurance companies have paid for the treatment of knee and hip joints since 2007 and for the treatment of vertebral joints since 2008. The shares in CO.DON AG are listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). Executive Board: Dirk Hessel (CEO), Ralf M. Jakobs (CFO).

Further information can be found at www.ihre-zellzuechter.de or www.codon.de

Xintela AB (publ)

Evy Lundgren-Åkerlund, CEO
Tel: 070-329 18 71
Email: evy@xintela.se
Medicon Village
223 81 Lund
www.xintela.se

For investor relations and media questions, please contact:

Mårten Svanberg, Laika Consulting
Tel: 070-362 70 05
Email: marten.svanberg@laika.se
www.laika.se

About Xintela

Xintela AB (publ) is a Swedish biomedical company active in the fields of regenerative medicine and cancer, with a focus on cartilage damage and brain tumours. The key to Xintela's business is the Company's patented marker technology, XINMARK™. Xintela's markers are specific proteins which sit as "recognition flags" on certain cell surfaces. The markers make it possible to identify and quality assure cartilage cells and stem cells and also to select a certain type of stem cells which can develop into cartilage cells. Through this technology, Xintela can, in a unique

Press release

Xintela AB (publ)

556780-3480

2017-05-22 14:00



way, quality assure stem cells for the repair of damaged cartilage. The XINMARK™-technology makes it also possible to direct antibody treatment to cells in glioblastoma brain tumours with the goal to slow down tumour growth. Xintela is listed on Nasdaq First North Stockholm since 22 March 2016. Xintela's Certified Adviser at Nasdaq First North is Erik Penser Bank AB, +46 8-463 80 00.

This information is information that Xintela AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. This information was submitted for publication through the agency of the contact persons set out above on 22 May 2017, at 14:00 CET.